INS and type 1 diabetes mellitus: Nine patients with long standing T1D randomized into three groups each received one of the escalating doses (0.5x107, 1.0 x107 or 2.0 x107 cells) of proinsulin-pulsed tolDC by intradermal injections twice as prime-boost one month apart (24).